SI4161929T1 - 1-(5-(2-cianopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kot zaviralec usp30 za uporabo pri zdravljenju mitohondrijske disfunkcije, raka in fibroze - Google Patents
1-(5-(2-cianopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kot zaviralec usp30 za uporabo pri zdravljenju mitohondrijske disfunkcije, raka in fibrozeInfo
- Publication number
- SI4161929T1 SI4161929T1 SI202130328T SI202130328T SI4161929T1 SI 4161929 T1 SI4161929 T1 SI 4161929T1 SI 202130328 T SI202130328 T SI 202130328T SI 202130328 T SI202130328 T SI 202130328T SI 4161929 T1 SI4161929 T1 SI 4161929T1
- Authority
- SI
- Slovenia
- Prior art keywords
- methylhexahydropyrrolo
- cyanopyridin
- carbonitrile
- oxazole
- fibrosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2008598.1A GB202008598D0 (en) | 2020-06-08 | 2020-06-08 | Novel compounds |
| GBGB2016758.1A GB202016758D0 (en) | 2020-10-22 | 2020-10-22 | Novel compounds |
| PCT/EP2021/065112 WO2021249909A1 (en) | 2020-06-08 | 2021-06-07 | 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis |
| EP21732212.2A EP4161929B1 (en) | 2020-06-08 | 2021-06-07 | 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI4161929T1 true SI4161929T1 (sl) | 2025-10-30 |
Family
ID=76444375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI202130328T SI4161929T1 (sl) | 2020-06-08 | 2021-06-07 | 1-(5-(2-cianopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kot zaviralec usp30 za uporabo pri zdravljenju mitohondrijske disfunkcije, raka in fibroze |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US12655152B2 (enExample) |
| EP (1) | EP4161929B1 (enExample) |
| JP (1) | JP2023528087A (enExample) |
| KR (1) | KR20230022215A (enExample) |
| CN (1) | CN115836073B (enExample) |
| AU (1) | AU2021286831A1 (enExample) |
| BR (1) | BR112022024794A2 (enExample) |
| CA (1) | CA3186148A1 (enExample) |
| CO (1) | CO2022017233A2 (enExample) |
| DK (1) | DK4161929T3 (enExample) |
| ES (1) | ES3040433T3 (enExample) |
| FI (1) | FI4161929T3 (enExample) |
| HR (1) | HRP20250891T1 (enExample) |
| HU (1) | HUE072598T2 (enExample) |
| IL (1) | IL298785B2 (enExample) |
| LT (1) | LT4161929T (enExample) |
| MD (1) | MD4161929T2 (enExample) |
| MX (1) | MX2022015608A (enExample) |
| PL (1) | PL4161929T3 (enExample) |
| PT (1) | PT4161929T (enExample) |
| RS (1) | RS67140B1 (enExample) |
| SI (1) | SI4161929T1 (enExample) |
| SM (1) | SMT202500343T1 (enExample) |
| WO (1) | WO2021249909A1 (enExample) |
| ZA (1) | ZA202213877B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021245186A1 (en) | 2020-06-04 | 2021-12-09 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| RS67140B1 (sr) * | 2020-06-08 | 2025-09-30 | Mission Therapeutics Ltd | 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze |
| WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| CN114646700B (zh) * | 2022-03-01 | 2023-10-20 | 浙江国邦药业有限公司 | 一种（s）-吡咯烷-2-甲腈盐酸盐的检测方法 |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
| WO2026098667A1 (zh) * | 2024-11-11 | 2026-05-15 | 长春金赛药业有限责任公司 | Usp30抑制剂化合物、药物组合物及其制备方法和应用 |
| GB202500610D0 (en) | 2025-01-16 | 2025-03-05 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665754A (en) | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| JP2003530384A (ja) | 2000-04-06 | 2003-10-14 | メルク フロスト カナダ アンド カンパニー | カテプシンシステインプロテアーゼ阻害薬 |
| AU2003263393A1 (en) | 2002-09-04 | 2004-03-29 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| WO2007119214A2 (en) | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| US8242271B2 (en) | 2007-06-04 | 2012-08-14 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| US20090264431A1 (en) | 2007-08-20 | 2009-10-22 | Palovich Michael R | Novel cathepsin c inhibitors and their use |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| UY31771A1 (es) | 2008-04-18 | 2009-09-30 | Inhibidores de catepsina c | |
| UY31770A1 (es) | 2008-04-18 | 2009-09-30 | Inhibidores de catepsina c | |
| UA105005C2 (uk) | 2008-06-16 | 2014-04-10 | Юніверсіті Оф Теннессі Рісерч Фаундейшн | Сполуки для лікування раку |
| CA2741666C (en) | 2008-10-31 | 2017-04-11 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| US8946231B2 (en) | 2009-03-23 | 2015-02-03 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| JP5852658B2 (ja) | 2010-09-24 | 2016-02-03 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | デユビキチナーゼ阻害剤およびその使用方法 |
| US20120309820A1 (en) | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| TW201524952A (zh) | 2013-03-15 | 2015-07-01 | Araxes Pharma Llc | Ｋｒａｓ ｇ１２ｃ之共價抑制劑 |
| JP6612751B2 (ja) | 2013-07-31 | 2019-11-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用 |
| US9963444B2 (en) | 2014-05-19 | 2018-05-08 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof |
| US20170095457A1 (en) | 2014-05-27 | 2017-04-06 | David Lonergan | Compositions and methods of delivery of deubiquitinase inhibitors |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| WO2016021629A1 (ja) | 2014-08-06 | 2016-02-11 | 塩野義製薬株式会社 | ＴｒｋＡ阻害活性を有する複素環および炭素環誘導体 |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| LT3277677T (lt) * | 2015-03-30 | 2021-05-25 | Mission Therapeutics Limited | 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai |
| EP3322702B1 (en) | 2015-07-14 | 2019-11-20 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| MA43753A (fr) * | 2016-03-24 | 2018-11-28 | Mission Therapeutics Ltd | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| US10968172B2 (en) | 2017-05-15 | 2021-04-06 | Mitobridge, Inc. | USP30 inhibitors |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| GB2563595B (en) | 2017-06-19 | 2020-04-15 | Edwards Ltd | Twin-shaft pumps |
| JP7208931B2 (ja) | 2017-06-20 | 2023-01-19 | ミッション セラピューティクス リミティド | Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類 |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| GB2571731A (en) | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| IL278291B2 (en) | 2018-05-17 | 2023-10-01 | Forma Therapeutics Inc | Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors |
| EP3837262B1 (en) | 2018-08-14 | 2026-06-17 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| EP4218934B1 (en) | 2018-10-05 | 2025-06-18 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| MX2022012578A (es) | 2020-04-08 | 2022-11-07 | Mission Therapeutics Ltd | N-cianopirrolidinas con actividad como inhibidores de usp30. |
| KR20230016674A (ko) | 2020-05-28 | 2023-02-02 | 미션 테라퓨틱스 엘티디 | 미토콘드리아 기능장애의 치료를 위한 usp30 억제제로서 n-(1-시아노피롤리딘-3-일)-5-(3-(트라이플루오로메틸)페닐)옥사졸-2-카복스아미드 유도체 및 상응하는 옥사다이아졸 유도체 |
| WO2021245186A1 (en) | 2020-06-04 | 2021-12-09 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| RS67140B1 (sr) * | 2020-06-08 | 2025-09-30 | Mission Therapeutics Ltd | 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze |
-
2021
- 2021-06-07 RS RS20250744A patent/RS67140B1/sr unknown
- 2021-06-07 JP JP2022575399A patent/JP2023528087A/ja active Pending
- 2021-06-07 PL PL21732212.2T patent/PL4161929T3/pl unknown
- 2021-06-07 CN CN202180040683.1A patent/CN115836073B/zh active Active
- 2021-06-07 LT LTEPPCT/EP2021/065112T patent/LT4161929T/lt unknown
- 2021-06-07 MD MDE20230409T patent/MD4161929T2/ro unknown
- 2021-06-07 KR KR1020237000509A patent/KR20230022215A/ko active Pending
- 2021-06-07 HU HUE21732212A patent/HUE072598T2/hu unknown
- 2021-06-07 US US18/008,352 patent/US12655152B2/en active Active
- 2021-06-07 MX MX2022015608A patent/MX2022015608A/es unknown
- 2021-06-07 EP EP21732212.2A patent/EP4161929B1/en active Active
- 2021-06-07 CA CA3186148A patent/CA3186148A1/en active Pending
- 2021-06-07 BR BR112022024794A patent/BR112022024794A2/pt unknown
- 2021-06-07 IL IL298785A patent/IL298785B2/en unknown
- 2021-06-07 SI SI202130328T patent/SI4161929T1/sl unknown
- 2021-06-07 ES ES21732212T patent/ES3040433T3/es active Active
- 2021-06-07 FI FIEP21732212.2T patent/FI4161929T3/fi active
- 2021-06-07 SM SM20250343T patent/SMT202500343T1/it unknown
- 2021-06-07 PT PT217322122T patent/PT4161929T/pt unknown
- 2021-06-07 DK DK21732212.2T patent/DK4161929T3/da active
- 2021-06-07 WO PCT/EP2021/065112 patent/WO2021249909A1/en not_active Ceased
- 2021-06-07 AU AU2021286831A patent/AU2021286831A1/en active Pending
- 2021-06-07 HR HRP20250891TT patent/HRP20250891T1/hr unknown
-
2022
- 2022-11-30 CO CONC2022/0017233A patent/CO2022017233A2/es unknown
- 2022-12-21 ZA ZA2022/13877A patent/ZA202213877B/en unknown
-
2026
- 2026-01-13 US US19/447,329 patent/US20260138984A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115836073B (zh) | 2024-08-27 |
| ZA202213877B (en) | 2024-07-31 |
| KR20230022215A (ko) | 2023-02-14 |
| DK4161929T3 (da) | 2025-08-18 |
| IL298785B2 (en) | 2026-03-01 |
| FI4161929T3 (fi) | 2025-07-30 |
| CO2022017233A2 (es) | 2023-03-07 |
| MD4161929T2 (ro) | 2025-10-31 |
| US20230312580A1 (en) | 2023-10-05 |
| CN115836073A (zh) | 2023-03-21 |
| JP2023528087A (ja) | 2023-07-03 |
| IL298785A (en) | 2023-02-01 |
| HUE072598T2 (hu) | 2025-11-28 |
| RS67140B1 (sr) | 2025-09-30 |
| PL4161929T3 (pl) | 2026-01-05 |
| EP4161929B1 (en) | 2025-04-30 |
| HRP20250891T1 (hr) | 2025-09-26 |
| IL298785B1 (en) | 2025-11-01 |
| AU2021286831A1 (en) | 2023-02-02 |
| PT4161929T (pt) | 2025-08-05 |
| ES3040433T3 (en) | 2025-10-30 |
| WO2021249909A1 (en) | 2021-12-16 |
| US12655152B2 (en) | 2026-06-16 |
| SMT202500343T1 (it) | 2025-11-10 |
| US20260138984A1 (en) | 2026-05-21 |
| LT4161929T (lt) | 2025-09-25 |
| CA3186148A1 (en) | 2021-12-16 |
| MX2022015608A (es) | 2023-03-03 |
| BR112022024794A2 (pt) | 2022-12-27 |
| EP4161929A1 (en) | 2023-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298785B2 (en) | 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-B]PYR-5(1H)-carbonitrile as a USP30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis | |
| IL288104B1 (en) | Heterocyclic compounds, pharmaceutical preparations containing them and their use for the treatment of cancer | |
| CA3148745A1 (en) | Kras g12d inhibitors | |
| IL288872B1 (en) | IMIDAZO[1,5-c]PYRIMIDIN-5-AMINE PERI-CONDENSED DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USES IN CANCER TREATMENT | |
| WO2008098104A8 (en) | Inhibitors of akt activity | |
| WO2017087808A8 (en) | Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers | |
| MX2021012418A (es) | Compuestos heterociclicos y sus usos. | |
| IL291388A (en) | Heterocyclic derivatives, pharmaceutical preparations and their use for the treatment or alleviation of cancer | |
| GEP20115230B (en) | Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 | |
| CA3264923A1 (en) | COMPOSITION INTENDED FOR USE IN THE TREATMENT OF FABRY'S DISEASE | |
| IL307402A (en) | The tercyclic derivatives, pharmaceutical compounds and their use in the treatment or amelioration of cancer | |
| MX2020012622A (es) | Tratamientos. | |
| AU2023411337A1 (en) | Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer | |
| EP4436565B8 (en) | Thioacrylamide derivatives for use in the prevention or treatment of liver fibrosis | |
| WO2008100653A3 (en) | Copper lowering treatment of cardiac disease | |
| EP4021906A4 (en) | N-(2-aminophenyl)-prop-2-enamide derivatives, and uses thereof in the treatment of cancer | |
| HUP2300462A1 (hu) | Imidazol-származékok és alkalmazásuk antifibrotikus szerként | |
| CA3277477A1 (en) | Heterocyclic compounds as ent inhibitors and compounds for use in the treatment of cancers | |
| CA3307803A1 (en) | Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19 | |
| HK40102271A (en) | 2h-indazole derivatives as irak4 inhibitors and their use in the treatment of disease | |
| HK40107074A (en) | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | |
| HK40115106A (en) | Heterocyclic compounds for use in the treatment of cancer | |
| HK40109976A (en) | 1,2-dihydroquinoline-2-ones for their use in the treatment of limb-girdle muscular dystrophy | |
| HK40088920A (en) | Methylthioninium compounds for use in the treatment of covid-19 | |
| CA3292535A1 (en) | Use of urolithin derivatives in the treatment of amyotrophic lateral sclerosis |